Scaffolds for blocking protein-protein interactions

Current Topics in Medicinal Chemistry

Volumn 7, Issue 10, 2007, Pages 928-942

  Hershberger, Stefan J ^a   Lee, Song Gil ^a   Chmielewski, Jean ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Calixarene scaffolds; Constrained helices; EVH1 domains; Kinase inducible activation domain; Quinoline based scaffolds

Indexed keywords

1,4 BENZODIAZEPINE 2,5 DIONE DERIVATIVE; 2,3',6',3' TERPYRIDINE; 3 INDOLEMETHANOL; BIPYRIDINE DERIVATIVE; BISIMIDAZOLE; CALIXARENE; CYCLODEXTRIN DERIVATIVE; CYTOCHROME C; IMIDAZOLE DERIVATIVE; LEIUROTOXIN I; LIGAND; MATRIX METALLOPROTEINASE INHIBITOR; NAPHTHALENE DERIVATIVE; PANCREAS POLYPEPTIDE; PEPTIDE DERIVATIVE; PEPTOID; POLYCYCLIC ETHER DERIVATIVE; PORPHYRIN; PROTEIN CD4M33; PROTEIN CD4M9; PROTEIN DERIVATIVE; PROTEINASE INHIBITOR; QUINOLINE DERIVATIVE; RUTHENIUM TRISBIPYRIDINE DERIVATIVE; TENDAMISTAT; TEREPHTHALAMIDE; TERPHENYL DERIVATIVE; THROMBIN INHIBITOR; TRISPYRIDYLAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALPHA HELIX; BETA SHEET; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PROTEOMICS; REVIEW;

ANIMALS; BINDING SITES; DRUG DESIGN; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR MIMICRY; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN INTERACTION MAPPING; PROTEINS; RECOMBINANT FUSION PROTEINS;

EID: 34447290912     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607780906726     Document Type: Review

References (110)

1. Toogood, P. L. Inhibition of protein-protein association by small molecules: Approaches and progress, J. Med. Chem., 2002, 45, 1543-1558.
2. Fletcher, S.; Hamilton, A. D. Targeting protein-protein interactions by rational design: mimicry of protein surfaces. J. R. Soc. Interface, 2006, 3, 215-233.
3. Yin, H.; Hamilton, A. D. Strategies for targeting protein-protein interactions with synthetic agents. Angew. Chem. Int. Ed., 2005, 44, 4130-4163.
4. Berg, T. Modulation of protein-protein interactions with small organic molocule. Angew. Chem. Int. Ed., 2003, 42, 2462-2481.
5. Zhao, L.; Chmielewski, J. Inhibiting protein-protein interactions using designed molecules. Curr. Opin. Struct. Biol., 2005, 15, 31-34.
6. Imperiali, B.; Ottesen, J. J. Design strategies for the construction of independently folded polypeptide motifs. Biopolymers, 1998, 47, 23-29.
7. Nygren, P. A.; Skerra, A. Binding proteins from alternative scaffolds. J. Immunol. Methods, 2004, 290, 3-28.
8. Chin, J. W.; Schepartz, A. Concerted evolution of structure and function in a miniature protein. J. Am. Chem. Soc., 2001, 123, 2929-2930.
9. Montclare, J. K.; Schepartz, A. Miniature homeodomains: High specificity without an N-terminal arm. J. Am. Chem. Soc., 2003, 125, 3416-3417.
10. Zondlo, N. J.; Schepartz, A. Highly specific DNA recognition by a designed miniature protein. J. Am. Chem Soc., 1999, 121, 6938-6939.
11. Chin, J. W.; Schepartz, A. Design and evolution of a miniature bcl-2 binding protein. Angew. Chem., Int. Ed., 2001, 40, 3806-3809.
12. Gemperli, A. C.; Rutledge, S. E.; Maranda, A.; Schepartz, A. Paralog-selective ligands for Bcl-2 proteins. J. Am. Chem. Soc., 2005, 127, 1596-1597.
13. Golemi-Kotra, D.; Mahaffy, R.; Footer, M. J.; Holtzman, J. H.; Pollard, T. D.; Theriot, J. A.; Schepartz, A. High affinity, paralog-specific recognition of the Mena EVH1 domain by a miniature protein. J. Am. Chem Soc., 2004, 126, 4-5.
14. Kritzer, J. A.; Zutshi, R.; Cheah, M.; Ran, F. A.; Webman, R.; Wongjirad, T. M.; Schepartz, A. Miniature protein inhibitors of the p53-hDM2 interaction. Chembiochem, 2006, 7, 29-31.
15. Volkman, H. M.; Rutledge, S. E.; Schepartz, A. Binding mode and transcriptional activation potential of high affinity ligands for the CBPKIX domain. J. Am. Chem. Soc., 2005, 127, 4649-4658.
16. Schneider, T. L.; Mathew, R. S.; Rice, K. P.; Tamaki, K.; Wood, J. L.; Schepartz, A. Increasing the kinase specificity of K252a by protein surface recognition. Org. Lett., 2005, 7, 1695-1698.
17. Vita, C.; Drakopoulou, E.; Vizzavona, J.; Rochette, S.; Martin, L.; Menez, A.; Roumestand, C.; Yang, Y. S.; Ylisastigui, L.; Benjouad, A.; Gluckman, J. C. Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein. Proc. Natl. Acad. Sci. USA, 1999, 96, 13091-13096.
18. Martin, L.; Stricher, F.; Misse, D.; Sironi, F.; Pugniere, M.; Barthe, P.; Prado-Gotor, R.; Freulon, I.; Magne, X.; Roumestand, C.; Mencz, A.; Lusso, P.; Veas, F.; Vita, C. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat. Biotechnol., 2003, 21, 71-76.
19. Jain, R. K.; Hamilton, A. D. Protein surface recognition by synthetic receptors based on a tetraphenylporphyrin scaffold. Org. Lett., 2000, 2, 1721-1723.
20. Aya, T.; Hamilton, A. D. Tetrabiphenylporphyrin-based receptors for protein surfaces show sub-nanomolar affinity and enhance unfolding. Bioorg. Med. Chem. Lett., 2003, 13, 2651-2654.
21. Takashima, H.; Shinkai, S.; Hamachi, I. Ru(bpy)(3)-based artificial receptors toward a protein surface: selective binding and efficient photoreduction of cytochrome C. Chem Comm., 1999, 2345-2346.
22. Gradl, S. N.; Felix, J. P.; Isacoff, E. Y.; Garcia, M. L.; Trauner, D. Protein surface recognition by rational design: Nanomolar ligands for potassium channels. J. Am. Chem. Soc., 2003, 125, 12668-12669.
23. Aviezer, D.; Cotton, S.; David, M.; Segev, A.; Khaselev, N.; Galili, N.; Gross, Z.; Yayon, A. Porphyrin analogues as novel antagonists of fibroblast growth factor and vascular endothelial growth factor receptor binding that inhibit endothelial cell proliferation, tumor progression, and metastasis. Cancer Res., 2000, 60, 2973-2980.
24. Blaskovich, M. A.; Lin, Q.; Delarue, F. L.; Sun, J.; Park, H. S.; Coppola, D.; Hamilton, A. D.; Sebti, S. M. Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice. Nat. Biotechnol., 2000, 18, 1065-1070.
25. Wei, Y.; McLendon, G. L.; Hamilton, A. D.; Case, M. A.; Purring, C. B.; Lin, Q.; Park, H. S.; Lee, C. S.; Yu, T. N. Disruption of protein-protein interactions: design of a synthetic receptor that blocks the binding of cytochrome c to cytochrome c peroxidase. Chem. Comm., 2001, 1580-1581.
26. Mecca, T.; Consoli, G. M. L.; Geraci, C.; Cunsolo, F. Designed calix[8]arene-based ligands for selective tryptase surface recognition. Bioorgan. Med. Chem., 2004, 12, 5057-5062.
27. Francese, S.; Cozzolino, A.; Caputo, L.; Esposito, C.; Martino, M.; Gaeta, C.; Troisi, F.; Neri, P. Transglutaminase surface recognition by peptidocalix[4]arene diversomers. Tetrahedron Lett., 2005, 46, 1611-1615.
28. DeLano, W. L. Unraveling hot spots in binding interfaces: progress and challenges. Curr. Opin. Struct. Biol., 2002, 12, 14-20.
29. Bogan, A. A.; Thom, K. S. Anatomy of hot spots in protein interfaces. J. Mol. Biol., 1998, 280, 1-9.
30. Berg, T. Use of "tethering" for the identification of a small molecule that binds to a dynamic hot spot on the interleukin-2 surface. Chembiochem, 2004, 5, 1051-1053.
31. Xu, Y.; Lu, H.; Kennedy, J. P.; Yan, X. X.; McAllister, L. A.; Yamamoto, N.; Moss, J. A.; Boldt, G. E.; Jiang, S. B.; Janda, K. D. Evaluation of "credit card" libraries for inhibition of HIV-1 gp41 fusogenic core formation. J. Comb. Chem., 2006, 8, 531-539.
32. Aachmann, F. L.; Otzen, D. E.; Larsen, K. L.; Wimmer, R. Structural background of cyclodextrin-protein interactions. Protein Eng., 2003, 16, 905-912.
33. Breslow, R.; Yang, Z. W.; Ching, R.; Trojandt, G.; Odobel, F. Sequence selective binding of peptides by artificial receptors in aqueous solution. J. Am. Chem. Soc., 1998, 120, 3536-3537.
34. Leung, D. K.; Yang, Z. W.; Breslow, R. Selective disruption of protein aggregation by cyclodextrin dimers. Proc. Natl. Acad. Sci. USA, 2000, 97, 5050-5053.
35. Orner, B. P.; Ernst, J. T.; Hamilton, A. D. Toward proteomimetics: Terphenyl derivatives as structural and functional mimics of extended regions of an alpha-hehix. J. Am. Chem Soc., 2001, 123, 5382-5383.
36. Ernst, J. T.; Kutzki, O.; Debnath, A. K.; Jiang, S.; Lu, H.; Hamilton, A. D. Design of a protein surface antagonist based on alpha-helix mimicry: Inhibition of gp41 assembly and viral fusion. Angew. Chem. Int. Ed., 2001, 41, 278-281.
37. Kutzki, O.; Park, H. S.; Ernst, J. T.; Omer, B. P.; Yin, H.; Hamilton, A. D. Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry. J. Am. Chem. Soc., 2002, 124, 11838-11839.
38. Yin, H.; Lee, G. I.; Sedey, K. A.; Kutzki, O.; Park, H. S.; Omer, B. P.; Ernst, J. T.; Wang, H. G.; Sebti, S. M.; Hamilton, A. D. Terphenyl-based bak BH3 alpha-helical proteomimectics as low-molecular-weight antagonists of Bcl-X-L. J. Am. Chem. Soc., 2005, 127, 10191-10196.
39. Yin, H.; Lee, G. I.; Park, H. S.; Payne, G. A.; Rodriguez, J. M.; Sebti, S. M.; Hamilton, A. D. Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction. Angew. Chem. Int. Ed., 2005, 44, 2704-2707.
40. Antuch, W.; Menon, S.; Chen, Q. Z.; Lu, Y. C.; Sakamuri, S.; Beck, B.; Schauer-Vukasinovic, V.; Agarwal, S.; Hess, S.; Domling, A. Design and modular parallel synthesis of a MCR derived alpha-helix mimetic protein-protein interaction inhibitor scaffold. Bioorg. Med. Chem. Lett., 2006, 16, 1740-1743.
41. Ernst, J. T.; Becerril, J.; Park, H. S.; Yin, H.; Hamilton, A. D. Design and application of an alpha-helix-mimetic scaffold based on an oligoamide-foldamer strategy: Antagonism of the bak BH3/Bcl-xL complex. Angew. Chem. Int Ed., 2003, 42, 535-539.
42. Yin, H.; Hamilton, A. D. Terephthalamide derivatives as mimetics of the helical region of Bak peptide target Bcl-xL protein. Bioorg. Med. Chem. Lett., 2004, 14, 1375-1379.
43. Yin, H.; Lee, G. I.; Sedey, K. A.; Rodriguez, J. M.; Wang, H. G.; Sebti, S. M.; Hamilton, A. D. Terephthalamide derivatives as mimetics of helical peptides: Disruption of the Bcl-x(L)/Bak interaction. J. Am. Chem. Soc., 2005, 127, 5463-5468.
44. Davis, J. M.; Truong, A.; Hamilton, A. D. Synthesis of a 2,3 ';6 ',3 "-terpyridine scaffold as an alpha-helix mimetic. Org. Lett., 2005, 7, 5405-5408.
45. Kim, I. C.; Hamilton, A. D. Diphenylindane-based proteomimetics reproduce the projection of the i, i+3, i+4, and i+7 residues on an alpha-helix. Org. Lett., 2006, 8, 1751-1754.
46. VanCompemolle, S. E.; Wiznycia, A. V.; Rush, J. R.; Dhanasekaran, M.; Baures, P. W.; Todd, S. C. Small molecule inhibition of hepatitis C virus E2 binding to CD81. Virology, 2003, 314, 371-380.
47. Wiznycia, A. V.; Baures, P. W. An improved method for the synthesis of dissymmetric N,N '-disubstituted imidazole-4,5-dicarboxamides. J. Org. Chem., 2002, 67, 7151-7154.
48. Cummings, M. D.; Schubert, C.; Parks, D. J.; Calvo, R. R.; LaFrance, L. V.; Lattanze, J.; Milkiewicz, K. L.; Lu, T. B. Substituted 1,4-benzodiazepine-2,5-diones as alpha-helix mimetic antagonists of the HDM2-p53 protein-protein interaction. Chem. Biol. Drug Des., 2006, 67, 201-205.
49. Parks, D. J.; LaFrance, L. V.; Calvo, R. R.; Milkiewicz, K. L.; Gupta, V.; Lattanze, J.; Ramachandren, K.; Carver, T. E.; Petrella, E. C.; Cummings, M. D.; Maguire, D.; Grasberger, B. L.; Lu, T. B. 1,4-benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR. Bioorg. Med. Chem Lett., 2005, 15, 765-770.
50. Fujii, N.; Haresco, J. J.; Novak, K. A. P.; Stokoe, D.; Kuntz, I. D.; Guy, R. K. A selective irreversible inhibitor targeting a PDZ protein interaction domain. J. Am. Chem. Soc., 2003, 125, 12074-12075.
51. Oguri, H.; Tanabe, S.; Oomura, A.; Umetsu, M.; Hirama, M. Synthesis and evaluation of alpha-helix mimetics based on a trans-flused polycyclic ether: sequence-selective binding to aspartate pairs in alpha-helical peptides. Tetrahedron Lett., 2006, 47, 5801-5805.
52. Stephens, O. M.; Kim, S.; Welch, B. D.; Hodsdon, M. E.; Kay, M. S.; Schepartz, A. Inhibiting HIV fusion with a beta-peptide foldamer. J. Am. Chem. Soc., 2005, 127, 13126-13127.
53. Kritzer, J. A.; Lear, J. D.; Hodsdon, M. E.; Schepartz, A. Helical beta-peptide inhibitors of the p53-hDM2 interaction. J. Am. Chem. Soc., 2004, 126, 9468-9469.
54. Sadowsky, J. D.; Schmitt, M. A.; Lee, H. S.; Umezawa, N.; Wang, S. M.; Tomita, Y.; Gellman, S. H. Chimeric (alpha/beta plus alpha)-peptide ligands for the BH3-recognition cleft of Bcl-x(L): Critical role of the molecular scaffold in protein surface recognition. J. Am. Chem. Soc., 2005, 127, 11966-11968.
55. Kirshenbaum, K.; Barron, A. E.; Goldsmith, R. A.; Armand, P.; Bradley, E. K.; Truong, K. T. V.; Dill, K. A.; Cohen, F. E.; Zuckermann, R. N. Sequence-specific polypeptoids: A diverse family of heteropolymers with stable secondary structure. Proc. Natl. Acad. Sci. USA, 1998, 95, 4303-4308.
56. Wu, C. W.; Sanborn, T. J.; Huang, K.; Zuckermann, R. N.; Barron, A. E. Peptoid oligomers with alpha-chiral, aromatic side chains: Sequence requirements for the formation of stable peptoid helices, J. Am. Chem. Soc., 2001, 123, 6778-6784.
57. Patch, J. A.; Barron, A. E. Helical peptoid mimics of magainin-2 amide. J. Am. Chem. Soc., 2003, 125, 12092-12093.
58. Seurynck, S. L.; Patch, J. A.; Barron, A. E. Simple, helical peptoid analogs of lung surfactant protein B. Chem. Biol., 2005, 12, 77-88.
59. Patch, J. A.; Kirshenbaum, K.; Seurynck, S. L., Zuckermann, R. N.; Barron, A. E. Versatile Oligo(N-Substituted) Glycines: The Many Roles of Peptoids in Drug Discovery. in Pseudo-peptides in Drug Development; P.E. Neilsen, Ed.; John Wiley & Sons: Hoboken, New Jersey, 2004; pp. 1-31.
60. Nguyen, J. T.; Turck, C. W.; Cohen, F. E.; Zuckermann, R. N.; Lim, W. A. Exploiting the basis of proline recognition by SH3 and WW domains: Design of n-substituted inhibitors. Science, 1998, 282, 2088-2092.
61. Hara, T.; Durell, S. R.; Myers, M. C.; Appella, D. H. Probing the structural requirements of peptoids that inhibit HDM2-p53 interactions. J. Am. Chem. Soc., 2006, 128, 1995-2004.
62. Nguyen, J. T.; Porter, M.; Amoui, M.; Miller, W. T.; Zackermann, R. N.; Lim, W. A. Improving SH3 domain ligand selectivity using a non-natural scaffold. Chem. Biol., 2000, 7, 463-473.
63. Daelemans, D.; Schols, D.; Witvrouw, M.; Pannecouque, C.; Hatse, S.; van Dooren, S.; Hamy, F.; Klimkait, T.; De Clercq, E.; Vandamme, A. M. A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: Inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry. Mol. Pharmacol., 2000, 57, 116-124.
64. Burkoth, T. S.; Beausoleil, E.; Kaur, S.; Tang, D. Z.; Cohen, F. E.; Zuckermann, R. N. Toward the synthesis of artificial proteins: The discovery of an amphiphilic helical peptoid assembly. Chem. Biol., 2002, 9, 647-654.
65. Patch, J. A.; Barron, A. E. Mimicry of bioactive peptides via non-natural, sequence-specific peptidomimetic oligomers. Curr. Opin. Chem. Biol., 2002, 6, 872-877.
66. Schafmeister, C. E.; Po, J.; Verdine, G. L. An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides. J. Am. Chem. Soc., 2000, 122, 5891-5892.
67. Williams, R. M.; Im, M. N. Asymmetric-Synthesis of Monosubs-tituted and Alpha,Alpha-Disubstituted Alpha-Amino-Acids Via Diastereoselective Glycine Enolate Alkylations. J. Am. Chem. Soc., 1991, 113, 9276-9286.
68. Walensky, L. D.; Kung, A. L.; Escher, I.; Malia, T. J.; Barbuto, S.; Wright, R. D.; Wagner, G.; Verdine, G. L.; Korsmeyer, S. J. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science, 2004, 305, 1466-1470.
69. Geistlinger, T. R.; Guy, R. K. Novel selective inhibitors of the interaction of individual nuclear hormone receptors with a mutually shared steroid receptor coactivator 2. J. Am. Chem. Soc., 2003, 125, 6852-6853.
70. Galande, A. K.; Bramlett, K. S.; Burris, T. P.; Wittliff, J. L.; Spatola, A. F. Thioether side chain cyclization for helical peptide formation: inhibitors of estrogen receptor-coactivator interactions. J. Pept. Res., 2004, 63, 297-302.
71. Calvo, J. C.; Choconta, K. C.; Diaz, D.; Orozco, O.; Bravo, M. M.; Espejo, F.; Salazar, L. M.; Guzman, F.; Patarroyo, M. E. An alpha helix conformationally restricted peptide is recognized by cervical carcinoma patients' sera. J. Med. Chem., 2003, 46, 5389-5394.
72. Sia, S. K.; Carr, P. A.; Cochran, A. G.; Malashkevich, V. N.; Kim, P. S. Short constrained peptides that inhibit HIV-1 entry. Proc. Natl. Acad. Sci. USA, 2002, 99, 14664-14669.
73. Fairlie, D. P.; Tyndall, J. D. A.; Reid, R. C.; Wong, A. K.; Abbenante, G.; Scanlon, M. J.; March, D. R.; Bergman, D. A.; Chai, C. L. L.; Burkett, B. A. Conformational selection of inhibitors and substrates by proteolytic enzymes: Implications for drug design and polypeptide processing. J. Med. Chem., 2000, 43, 1271-1281.
74. Harper, J. D.; Lansbury, P. T. Models of amyloid seeding in Alzheimier's disease and scrapie: Mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem., 1997, 66, 385-407.
75. Moebius, U.; Clayton, L. K.; Abraham, S.; Diener, A.; Yunis, J. J.; Harrison, S. C.; Reinherz, E. L. Human-Immunodeficiency-Virus Gp120 Binding C'c" Ridge of Cd4 Domain-1 Is Also Involved in Interaction with Class-Ii Major Histocompatibility Complex-Molecules. Proc. Natl. Acad. Sci. USA, 1992, 89, 12008-12012.
76. Barreiro, P.; Soriano, V.; Blanco, F.; Casimiro, C.; de la Cruz, J. J.; Gonzalez-Lahoz, J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS, 2000, 14, 807-812.
77. Loughlin, W. A.; Tyndall, J. D. A.; Glenn, M. P.; Fairlie, D. P. Beta-Strand Mimetics. Chem. Rev. 2004, 104, 6085-6117.
78. Barresinoussi, F.; Chermann, J. C.; Rey, F.; Nugeyre, M. T.; Chamaret, S.; Gruest, J.; Dauguet, C.; Axlerblin, C.; Vezinetbrun, F.; Rouzioux, C.; Rozenbaum, W.; Montagnier, L. Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune-Deficiency Syndrome (Aids). Science, 1983, 220, 868-871.
79. Zutshi, R.; Franciskovich, J.; Shultz, M.; Schweitzer, B.; Bishop, P.; Wilson, M.; Chmielewski, J. Targeting the dimerization interface of HIV-1 protease: Inhibition with cross-linked interfacial peptides. J. Am. Chem. Soc., 1997, 119, 4841-4845.
80. Shultz, M. D.; Bowman, M. J.; Ham, Y. W.; Zhao, X. M.; Tora, G.; Chmielewski, J. Small-molecule inhibitors of HIV-1 protease dimerization derived from cross-linked interfacial peptides. Angew. Chem. Int. Ed., 2000, 39, 2710-2713.
81. Shultz, M. D.; Ham, Y. W.; Lee, S. G.; Davis, D. A.; Brown, C.; Chmielewski, J. Small-molecule dimerization inhibitors of wild-type and mutant HIV protease: A focused library approach. J. Am. Chem. Soc., 2004, 126, 9886-9887.
82. Lee, S. G.; Chmielewski, J. Rapid synthesis and in situ screening of potent HIV-1 protease dimerization inhibitors. Chem. Biol., 2006, 13, 421-426.
83. Bowman, M. J.; Byrne, S.; Chmielewski, J. Switching between allosteric and dimerization inhibition of HIV-1 protease. Chem. Biol., 2005, 12, 439-444.
84. Bouras, A.; Boggetto, N.; Benatalah, Z.; de Rosny, E.; Sicsic, S.; Reboud-Ravaux, M. Design, synthesis, and evaluation of conformationally constrained tongs, new inhibitors of HIV-1 protease dimerization. J. Med. Chem., 1999, 42, 957-962.
85. Merabet, N.; Dumond, J.; Collinet, B.; Van Baelinghem, L.; Boggetto, N.; Ongeri, S.; Ressad, F.; Reboud-Ravaux, M.; Sicsic, S. New Constrained "Molecular Tongs" Designed to Dissociate HIV-1 Protease Dimer. J. Med. Chem., 2004, 47, 6392-6400.
86. Glenn, M. P.; Fairlie, D. P. Mimetics of the Peptide Beta-Strand. Mini Rev. Med. Chem., 2002, 2, 433-445.
87. Krishnan, R.; Zhang, E.; Hakansson, K.; Arni, R. K.; Tulinsky, A.; Lim-Wilby, M. S. L.; Levy, O. E.; Semple, J. E.; Brunck, T. K. Highly selective mechanism-based thrombin inhibitors: Structures of thrombin and trypsin inhibited with rigid peptidyl aldehydes. Biochemistry, 1998, 37, 12094-12103.
88. Levy, O. E.; Semple, J. E.; Lim, M. L.; Reiner, J.; Rote, W. E.; Dempsey, E.; Richard, B. M.; Zhang, E.; Tulinsky, A.; Ripka, W. C.; Nutt, R. F. Potent and selective thrombin inhibitors incorporating the constrained arginine mimic L-3-piperidyl(N-guanidino)alanine at P-1. J. Med. Chem., 1996, 39, 4527-4530.
89. Bernstein, P. R.; Andisik, D.; Bradley, P. K.; Bryant; C. B.; Ceccarelli, C.; Damewood, J. R.; Earley, R.; Edwards, P. D.; Feeney, S.; Gomes, B. C.; Kosmider, B. J.; Steelman, G. B.; Thomas, R. M.; Vacek, E. P.; Veale, C. A.; Williams, J. C.; Wolanin, D. J.; Woolson, S. A. Nonpeptidic Inhibitors of Human-Leukocyte Elastase. 3. Design, Synthesis, X-Ray Crystallographic Analysis, and Structure-Activity-Relationships for a Series of Orally-Active 3-Amino-6-Phenylpyridin-2-One Trifluoromethyl Ketones. J. Med. Chem., 1994, 37, 3313-3326.
90. Smith, A. B.; Nittoli, T.; Sprengeler, P. A.; Duan, J. J. W.; Liu, R. Q.; Hirschmann, R. F. Design, synthesis, and evaluation of a pyrrolinone-based matrix metalloprotease inhibitor. Org. Lett., 2000, 2, 3809-3812.
91. Lam, P. Y. S.; Jadhav, P. K.; Eyermann, C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, Y. N.; Chang, C. H.; Weber, P. C.; Jackson, D. A.; Sharpe, T. R.; Ericksonviitanen, S. Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as Hiv Protease Inhibitors. Science, 1994, 263, 380-384.
92. Debnath, A. K. Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: Application of comparative molecular field analysis. J. Med. Chem., 1999, 42, 249-259.
93. Rodgers, J. D.; Lam, P. Y. S.; Johnson, B. L.; Wang, H. S.; Ko, S. S.; Seitz, S. P.; Trainor, G. L.; Anderson, P. S.; Klabe, R. M.; Bacheler, L. T.; Cordova, B.; Garber, S.; Reid, C.; Wright, M. R.; Chang, C. H.; Erickson-Viitanen, S. Design and selection of DMP 850 and DMP 851: the next generation of cyclic urea HIV protease inhibitors. Chem. Biol., 1998, 5, 597-608.
94. Phillips, S. T.; Rezac, M.; Abel, U.; Kossenjans, M.; Bartlett, P. A. "tides": The 1,2-dihydro-3(6H)-pyridinone unit as a beta-strand mimic. J. Am. Chem. Soc., 2002, 124, 58-66.
95. Phillips, S. T.; Blasdel, L. K.; Bartlett, P. A. tide-stabilized beta-hairpins. J. Org. Chem., 2005, 70, 1865-1871.
96. Rose, G. D.; Gierasch, L. M.; Smith, J. A. Turns in Peptides and Proteins. Adv. Protein Chem., 1985, 37, 1-109.
97. Souers, A. J.; Ellman, J. A. beta-turn mimetic library synthesis: scaffolds and applications. Tetrahedron, 2001, 57, 7431-7448.
98. Eguchi, M.; Kahn, M. Design, Synthesis, and Application of Peptide Secondary Structure Mimetics. Mini Rev. Med. Chem., 2002, 2, 447-462.
99. Kee, S.; Jois, S. D. S. Design of beta-turn based therapeutic agents. Curr. Pharm. Des., 2003, 9, 1209-1224.
100. Hirschmann, R.; Nicolaou, K. C.; Pietranico, S.; Salvino, J.; Leahy, E. M.; Sprengeler, P. A.; Furst, G.; Smith, A. B.; Strader, C. D.; Cascieri, M. A.; Candelore, M. R.; Donaldson, C.; Vale, W.; Maechler, L. Nonpeptidal Peptidomimetics with a Beta-D-Glucose Scaffolding - a Partial Somatostatin Agonist Bearing a Close Structural Relationship to a Potent, Selective Substance-P Antagonist. J. Am. Chem. Soc., 1992, 114, 9217-9218.
101. Hirschmann, R.; Nicolaou, K. C.; Pietranico, S.; Leahy, E. M.; Salvino, J.; Arison, B.; Cichy, M. A.; Spoors, P. G.; Shakespeare, W. C.; Sprengeler, P. A.; Hamley, P.; Smith, A. B.; Reisine, T.; Raynor, K.; Maechler, L.; Donaldson, C.; Vale, W.; Freidinger, R. M.; Cascieri, M. R.; Strader, C. D. De-Novo Design and Synthesis of Somatostatin Nonpeptide Peptidomimetics Utilizing Beta-D-Glucose as a Novel Scaffolding J. Am. Chem. Soc., 1993, 115, 12550-12568.
102. Etzkorn, F. A.; Guo, T.; Lipton, M. A.; Goldberg, S. D.; Bartlett, P. A. Cyclic Hexapeptides and Chimeric Peptides as Mimics of Tendamistat. J. Am. Chem. Soc., 1994, 116, 10412-10425.
103. Virgilio, A. A.; Ellman, J. A. Simultaneous Solid-Phase Synthesis of Beta-Turn Mimetics; Incorporating Side-Chain Functionality. J. Am. Chem. Soc., 1994, 116, 11580-11581.
104. Souers, A. J.; Virgilio, A. A.; Rosenquist, A.; Fenuik, W.; Ellman, J. A. Identification of a patent heterocyclic ligand to somatostatin receptor subtype 5 by the synthesis and screening of beta-turn mimetic libraries. J. Am. Chem. Soc., 1999, 121, 1817-1825.
105. Gademann, K.; Ernst, M.; Hoyer, D.; Seebach, D. Synthesis and biological evaluation of a cyclo-beta-tetrapeptide as a somatostatin analogue. Angew. Chem. Int. Ed., 1999, 38, 1223-1226.
106. Maliartchouk, S.; Feng, Y. B.; Ivanisevic, L.; Debeir, T.; Cuello, A. C.; Burgess, K.; Saragovi, H. U. A designed peptidomimetic agonistic ligand of TrkA nerve growth factor receptors. Mol. Pharmacol., 2000, 57, 385-391.
107. Feng, Y. B.; Wang, Z. C.; Jin, S.; Burgess, K. SNAr cyclizations to form cyclic peptidomimetics of beta-turns. J. Am. Chem. Soc., 1998, 120, 10768-10769.
108. Lee, H. B.; Zaccaro, M. C.; Pattarawarapan, M.; Roy, S.; Saragovi, H. U.; Burgess, K. Syntheses and activities of new C-10 beta-turn peptidomimetics. J. Org. Chem., 2004, 69, 701-713.
109. Ulysse, L. G.; Chmielewski, J. A light-activated beta-turn scaffold within a somatostatin analog: NMR structure and biological activity. Chem. Biol. Drug Des., 2006, 67, 127-136.
110. Blomberg, D.; Kreye, P.; Fowler, C.; Brickmann, K.; Kihlberg, J. Synthesis and biological evaluation of leucine enkephalin turn mimetics. Org. Biomol. Chem., 2006, 4, 416-423.